



News Release

Suven Life secures Five (5) Product Patents for their NCEs in Australia, Europe, Hong kong, Israel and Norway

HYDERABAD, INDIA (Apr 24, 2015) – Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from Australia (2010340745), one (1) product patent from Europe (2121602), one (1) product patent from Hong kong (1159626), one (1) product patent from Israel (211747) and one (1) product patent from Norway (335838) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The granted claims of the patents include the class of **selective 5-HT compounds discovered by Suven** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of **twenty one (21) granted patents from Australia, fifteen (15) granted patents from Europe, sixteen (16) product patents from Hong Kong, four (4) product patents from Israel and five (5) product patents from Norway**. These granted patents are exclusive intellectual property of Suven and are achieved through the **internal discovery research** efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **The Company has eleven (11) internally-discovered therapeutic drug candidates currently** in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to Phase 2 ready **developmental candidate SUVN-502** for and Phase1 candidate **SUVN-G3031** for **Alzheimer's disease and Schizophrenia**.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;